Development of lipid nanoparticles for transdermal loteprednol etabonate delivery
Yükleniyor...
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Taylor and Francis
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Aim Loteprednol etabonate (LE) is a new generation corticosteroid that is used for the treatment of inflammatory and allergic conditions of the eye. Therefore, solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) were attempted to improve for transdermal LE delivery for the first time. Methods SLN and NLC were produced by hot homogenization and ultrasonication technique. Their physical stability was monitored for 3 months of storage. Drug release and permeation of SLN and NLC through the porcine skin were investigated. Results It was determined that SLN and NLC mean particle size as 139.1 nm had a homogeneous particle size distribution (∼0,169 PI) and mean charge as -23.6. They were found to be stable both physically and chemically at room temperature. Conclusion SLN and NLC formulations of LE can be stated among the systems that can be an alternative to conventional systems with less side-effect in the treatment of inflammatory problems.
Açıklama
Anahtar Kelimeler
Loteprednol Etabonate, Nanostructured Lipid Carriers, Solid Lipid Nanoparticles, Topical Corticosteroids, Transdermal Delivery
Kaynak
Journal of Microencapsulation
WoS Q Değeri
Q2
Scopus Q Değeri
Q2
Cilt
39
Sayı
4
Künye
Üner, B., Özdemir, S., Taş, Ç., Özsoy, Y., & Üner, M.. (2022). Development of lipid nanoparticles for transdermal loteprednol etabonate delivery. Journal of Microencapsulation, 39(4), pp. 327-340. https://doi.org/10.1080/02652048.2022.2079744
